Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    No significant changes detected between the previous and current page versions. The content and study details appear unchanged aside from minor layout tweaks.
    Difference
    0.4%
    Check dated 2025-11-03T20:34:46.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    35 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    4%
    Check dated 2025-10-06T04:51:01.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    Upgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T02:54:35.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Revision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.
    Difference
    0.2%
    Check dated 2025-09-14T18:53:34.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.2%
    Check dated 2025-09-07T13:48:38.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of various chemical compounds related to azacitidine and pembrolizumab. Notably, several previous entries related to genetic diseases and specific antineoplastic agents have been removed.
    Difference
    3%
    Check dated 2025-08-31T11:35:31.000Z thumbnail image

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.